课题基金 / 基金详情

The role of protein tyrosine phosphatases regulating Eph RTK-signalling and modulating invasive tumour cell properties.

The role of protein tyrosine phosphatases regulating Eph RTK-signalling and modulating invasive tumour cell properties.
蛋白酪氨酸磷酸酶调节 Eph RTK 信号传导和调节侵袭性肿瘤细胞特性的作用。
批准号:
nhmrc : 436774
负责人:
A/Pr Martin Lackmann
金额:
$20.26万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2009-12-31

项目摘要

项目成果

A/Pr Martin Lackmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Ephs and interacting ephrins are proteins on the cell surface, which enable orientation of cells that move within the body tissues and organs, but also in tumours. Eph proteins have tyrosine kinase enzyme activity that becomes active after binding ephrins on neighbouring cells. Once active, they instruct these cells to change their shape and their adhesion to the substratum or between each other, and to become more motile. In adult organisms Ephs and ephrins are low in most cells, but they re-appear in many tumors. For example, when normal cells in the skin (melanocytes) become tumor cells, they often will have Ephs and ephrins on their surface. It is believed that these proteins will now affect if these melanoma cells will migrate and to which locations within the body. In our studies we will examine what controls the activity of Eph proteins. In particular, a class of enzymes called tyrosine phosphatases are known to regulate the function of tyrosine kinase receptors, however it is not clear which particular phosphatase regulates EphA3, the focus of our studies. We will find out, which set of phosphatases regulates EphA3 function and whether exposure to oxidative conditions, such as UV radiation, also activates Ephs and instructs tumour cells to become more motile and to invade other areas of the body. The understanding of this mechanism will help to understand the cause of cancers such as melanoma and might offer possibilities to optimise new strategies for its treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antibody-based inhibition of ADAM10 as cancer immunotherapy
  • 批准号:
    nhmrc : 1067609
  • 项目类别:
    Project Grants
  • 资助金额:
    $43.53万
  • 财政年份:
    2014
  • 负责人:
    A/Pr Martin Lackmann
  • 依托单位:
Control of gastrointestinal tumour progression by therapeutic interference with myeloid derived cells
  • 批准号:
    nhmrc : 1067244
  • 项目类别:
    Project Grants
  • 资助金额:
    $50.59万
  • 财政年份:
    2014
  • 负责人:
    A/Pr Martin Lackmann
  • 依托单位:
Can inhibition of myeloid cell function suppress gastro-intestinal cancer?
  • 批准号:
    nhmrc : GNT1067244
  • 项目类别:
    Project Grants
  • 资助金额:
    $72.75万
  • 财政年份:
    2014
  • 负责人:
    A/Pr Martin Lackmann
  • 依托单位:
Inhibiting tumour growth by targeting EphA3 and disrupting tumour stromal and vascular microenvironment
  • 批准号:
    nhmrc : 1049942
  • 项目类别:
    Project Grants
  • 资助金额:
    $43.02万
  • 财政年份:
    2013
  • 负责人:
    A/Pr Martin Lackmann
  • 依托单位:
国内基金
海外基金
子宫内膜间质与巨噬细胞之间通过Protein S-MerTK-Apelin信号对 话促进子宫腺肌病蜕膜化缺陷的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    吕海宁
  • 依托单位:
有翅与无翅蚜虫差异分泌唾液蛋白Cuticular protein在调控植物细胞壁免疫中的功能
  • 批准号:
    32372636
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    郭慧娟
  • 依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
  • 批准号:
    82371054
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郭涛
  • 依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
  • 批准号:
    82370976
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    郑凌艳
  • 依托单位: